Navigation Links
ThromboGenics Announces Half Year Results 2008
Date:8/28/2008

r patients.

The first Phase l study showed that TB-403 was safe and well tolerated,

with a pharmacokinetic profile which would allow it to be developed as

a treatment for cancer. TB-403 has moved into a Phase Ib trial. This

study will look at the tolerability, pharmacokinetics and

pharmacodynamics of TB-403 in patients with advanced cancer.

- Microplasmin: Positive results announced in Phase II

clinical trials for ophthalmic indications. Positive results were

reported in ThromboGenics' Phase IIb MIVI III trial in patients with a

number of back of the eye conditions. The trial showed that the most

effective dose of microplasmin studied (125 micro g) was able to

resolve the underlying disease in approximately 30% of patients and

consequently achieved the avoidance of surgical intervention in those

patients.

Further positive six month follow-up results from the Phase IIa MIVI IIT trial, designed to evaluate both the safety and efficacy of microplasmin injection for the treatment of vitreomacular traction, were presented at the Euretina Congress in Vienna, Austria in June.

Investor Highlights

ThromboGenics has continued to work to broaden the Company's shareholder base. In July, ThromboGenics announced the acquisition of an 8% stake in the Company by a group of private investors based in Belgium in a transaction coordinated by Petercam. Their stake was purchased from Biggar Limited, a charitable foundation that is ThromboGenics' largest shareholder. Biggar intends to remain an important shareholder in ThromboGenics for the long term.

Financial Summary

- In the first six months of 2008, revenue amounted to EUR30.3

million. This much higher level of revenue is due to Roche's upfront

payment following the signed co-development deal on TB-403. Operating

expenses were EUR13.0 million in the first half, the majority of which

were due
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
2. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
3. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
4. ThromboGenics N.V. - Business Update
5. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
6. ThromboGenics Announces 2007 Full Year Results
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
9. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
10. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
11. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... August 21, 2014 2014 ... Industry” is a professional and in-depth research ... report provides basic Seaweed Fertilizer information, including ... chain structure as well as industry overview. ... including domestic market as well as global ...
(Date:8/21/2014)... Aug. 21, 2014  Decision Resources Group finds ... and Mexico ... several newly approved agents, the anticipated label extension ... the launch of emerging biologics will substantially increase ... the emerging IL-5 inhibitors will introduce a new dynamic ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Pursuit ... selling optimization technology and services for Life Sciences ... “Grading Pharma’s Use of New Commercial Sales Models” ... & Analytics. , The article examines some innovative ... that are being tested in the pharmaceutical market. ...
(Date:8/20/2014)... Aug. 20, 2014 Clintrax Global, Inc., ... in Raleigh, NC , recently ... as Vice President of Administration. ... all corporate processes, including their alignment with company ... Brad worked as an HR executive, specializing in ...
Breaking Biology Technology:Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Clintrax Global, Inc. Announces Addition to Executive Team 2
... new University of Colorado Boulder study shows that huge ... feeding pythons promote healthy heart growth, results that may ... Professor Leslie Leinwand and her research team found the ... fats and oils -- in the blood of Burmese ...
... Stir this clear liquid in a glass vial and ... protein-like structures emerge, ready to detect molecules or catalyze ... Bond,s arsenal -- rather, the latest research from the ... Laboratory (Berkeley Lab) scientists unveiling how slim sheets ...
... CLARA, Calif. and ALISO VIEJO, Calif., Oct. 27, 2011 ... and Ambry Genetics today announced an agreement under which ... System for exome sequencing services. (Logo: ... focused on delivering the highest quality results for exome ...
Cached Biology Technology:CU-Boulder python study may have implications for human heart health 2CU-Boulder python study may have implications for human heart health 3CU-Boulder python study may have implications for human heart health 4Shaken, not stirred: Berkeley lab scientists spy molecular maneuvers 2Agilent Technologies Signs Agreement to Supply Target Enrichment System to Ambry Genetics for Exome Sequencing 2
(Date:8/21/2014)... team has successfully replicated one of the crucial steps ... by sunlight which could manufacture hydrogen as a fuel. ... is an exciting prospect to use them to create ... Kastoori Hingorani, from the ARC Centre of Excellence for ... , Hydrogen offers potential as a zero-carbon replacement for ...
(Date:8/20/2014)... LAKE CITY Researchers at Huntsman Cancer Institute (HCI) at ... forms of the gene that encodes BCR-ABL, the unregulated ... According to the American Cancer Society, nearly 6,000 new ... Drugs already in use, called tyrosine kinase inhibitors (TKIs), ... They do not cure CML but control it in ...
(Date:8/20/2014)... approximately 3 million infants, a team of scientists across ... Massachusetts Medical School, have shown that newborn screening for ... public health newborn screening programs. Data from 11 newborn ... the Journal of the American Medical Association ... newborns is higher than previously thought and believed to ...
Breaking Biology News(10 mins):Water and sunlight the formula for sustainable fuel 2Blueprint for next generation of chronic myeloid leukemia treatment 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3
... release is available in Spanish . , ... viable alternative to petroleum-based packaging products, according to a ... Tomasula for a new book, "Dairy-Derived Ingredients: Food ... by an international team of contributors and published by ...
... "original insect wrangler" who tamed 25,000 roaches, and trained ... of the Lambs," headlines the Southwest,s first Social Insect ... Garden. Designed for inquiring minds and families, the ... Arizona State University, their favorite critters and the public. ...
... breeding and high-intensity x-rays is being used by ... Research Council (BBSRC) to explore the possibility of ... potentially life-saving mineral enriched flour. The research is ... quarterly highlights magazine of BBSRC. Scientists from ...
Cached Biology News:Potential of dairy-based package wraps outlined 2Insect wranglers invade the garden at Southwestern science EXPO 2Scientists using X-ray vision to produce more nutritious flour 2
... Life Sciences provides cost effective cell culture ... or monoclonal antibodies. Quality at a reasonable ... you require research or commercial product, we ... methods such as roller bottles, hollow fiber, ...
... for hunting and analyzing the rare ... EST sequencing projects, microarrays, functional screenings ... well suited for the normalization of ... though, is specially developed for normalization ...
... Application: The Panorama Mouse/Rat Tissue Extract Protein ... expression in various tissue extracts. The expression ... detected using a protein specific antibody. When ... is visualized by a sensitive chemiluminescent or ...
... StabilGuard Choice Microsphere/Microarray Stabilizer is a ... Plus Stabilizer. This product is an ... a PBS buffer (phosphate buffered saline), pH ... a combination of 0.02% methylisothiazolone and 0.02% ...
Biology Products: